AbbVie Inc. (ABBV) Q4 2025 (USD): Adj. EPS 2.71 (exp. 2.65), Revenue 16.6bln (exp. 16.41bln); Q4 results include unfavourable impact of 0.71/SHR related to acquired IPR&D and milestones expense
Importance
Level 1
Drug Breakdown:
- Skyrizi 5.01bln
- Rinvoq 2.37bln (exp. 2.41bln)
- Humira 1.25bln
Guidance:
- FY26 adj. EPS view 14.37-14.57 (exp. 14.22).
#UNITED STATES#USD#EUR#JAPAN#JPY#UNITED KINGDOM#GBP#EUROPE#ABBVIE INC#ABBV.US#IMPORTANT#FOREX#EQUITIES#METALS#EU SESSION#US SESSION#BIOTECHNOLOGY#METALS & MINING#BIOTECHNOLOGY (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#S&P 500 INDEX#ABBVIE INC#ABBV#DXY#US EQUITIES